PDGFRB and neoplasm: Sorafenib is a tyrosine kinase inhibitor directed against several targets (including vascular-endothelial growth factor VEGFR2, platelet-derived growth factor (PDGFR)-b and Raf kinase) that has demonstrated the ability to inhibit tumor proliferation and angiogenesis in vitro.